Skip to main content
OpenTrials

Clinical trial condition

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Explore clinical trials studying Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Study availability and eligibility vary by location and protocol.

601 public trials 70 recruiting studies
Refine in advanced search Browse all conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive trial results

Completed

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

NCT01744665

Conditions
Bone Marrow Diseases, CML, Chronic Disease, +11 more
Locations
  • University of Alabama Comprehensive Cancer Center University of Alabama (8) Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Banner MD Anderson (2) Gilbert, Arizona, United States
  • Scottsdale Healthcare/TGen Clinical Research Service SC Scottsdale, Arizona, United States
  • Highlands Oncology Group Fayetteville, Arkansas, United States
View all 54 locations
View Trial Details
Completed

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +42 more
Locations
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
  • LDS Hospital Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

NCT00789776

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +49 more
Locations
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
  • Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States
  • Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Completed

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

NCT00036738

Conditions
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Crisis, +31 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

NCT00003145

Conditions
Accelerated Phase of Disease, Bone Marrow Diseases, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, +16 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Stanford University Hospitals and Clinics Stanford, California, United States
  • University of Colorado Denver, Colorado, United States
  • Baylor University Medical Center Dallas, Texas, United States
View Trial Details
Completed

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

NCT01527045

Conditions
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Blood Protein Disorders, +57 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details

Related conditions